Optimizing the progress of studying bio-marked compounds in early detection of Serum cancer.

April 17, 2007 - Epinomics multinational joint stock company has released a study at a high-level meeting of the Cambridge Institute of Technical Health in Boston, Massachussetts, USA, to speed up research progress. To save genes, to test proprietary DNA methylation biochemical compounds for early detection of various types of serum cancers.

Dr. DeVos , Vice President of the Department of Developmental Diagnosis of the company Epigenomics, gave data on the optimization of research progress achieved from experiments of DNA biochemical markers of methylation The largest serum ever, including several hundred colorectal cancer patients and many individuals are being monitored over the years.

The presentation entitled 'Optimizing the detection of serum DNA-based biomarkers has addressed the research progress requirements to detect tumors in a sensitive and rewarding manner. reliable - taking DNA from the tumor in the blood with sensitive and reliable DNA methylation DNA markers, for example by using Septin 9; The biochemical compound for colorectal cancer has been registered exclusively by Epigenomic.

Serum (Photo: Terradaily.com)

Dr. deVos provided evidence that using the MetylLight technique and the proprietary HM technique of the Epigenomics company to measure the methyl-impregnated Septin 9, the equivalent DNA could be detected. with about two cells of the tumor in a sample.

Furthermore, the data show that Epigenomics has successfully standardized the serum sampling process and has optimized the recovery of free floating DNA from serum samples and preparation for methyl analysis. Chemical treatment with proprietary bisulfite (Na ₂ S ₄ O ₈ ) treatments.

Epigenomics used this experimental process at the end of 2006 to demonstrate that the presence of DNA Septin 9 impregnated with serum methyl certainly found the presence of tumors at all. both stages in patients with colorectal cancer with a high sensitivity and accuracy.

'We believe that the deep understanding we have from the key determinants of research progression in early detection of colorectal cancer allows us to accelerate the genetic testing process. to find biochemical markers of methylation of DNA in the body fluids and this process can be applied in finding other cancer markers ' - Christain Piepenbrock, corporate director Epigenomics comment. ' This view also matches the miraculous results we have achieved in the prostate cancer diagnosis program last year. "

Based on the results of these studies and developed by Dr. deVos, Epigenomics is optimizing the testing process in genes in terms of cost, time, and simplicity of use. daily clinical.

Danh Phuong